Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Myriad Genetics Inc (MYGN)

Myriad Genetics Inc (MYGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,632,015
  • Shares Outstanding, K 78,055
  • Annual Sales, $ 154,600 K
  • Annual Income, $ -44,200 K
  • 60-Month Beta 1.57
  • Price/Sales 3.99
  • Price/Cash Flow 279.21
  • Price/Book 3.11
Trade MYGN with:

Options Overview

Details
  • Implied Volatility 62.85%
  • Historical Volatility 37.36%
  • IV Percentile 23%
  • IV Rank 25.12%
  • IV High 109.94% on 04/19/21
  • IV Low 47.05% on 08/17/21
  • Put/Call Vol Ratio 0.01
  • Today's Volume 100
  • Volume Avg (30-Day) 142
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 429
  • Open Int (30-Day) 1,369

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.09
  • Number of Estimates 5
  • High Estimate 0.01
  • Low Estimate -0.19
  • Prior Year -0.19
  • Growth Rate Est. (year over year) +52.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.25 +7.90%
on 09/15/21
36.95 -8.75%
on 08/30/21
+0.17 (+0.51%)
since 08/17/21
3-Month
28.30 +19.16%
on 06/21/21
36.95 -8.75%
on 08/30/21
+3.05 (+9.94%)
since 06/17/21
52-Week
11.76 +186.73%
on 09/24/20
36.95 -8.75%
on 08/30/21
+21.18 (+168.90%)
since 09/17/20

Most Recent Stories

More News
Predisposition Biomarkers Market- Expected Growth and its Factors, CAGR, Industry Size, Business Prospects and Forecast 2030

Research Nester published a report titled which delivers detailed overview of the global predisposition biomarkers market in terms of market segmentation by type, application, end-user, and by region....

DHR : 324.53 (+0.16%)
MYGN : 33.72 (+3.37%)
TMO : 596.80 (+6.49%)
BIO : 788.35 (+0.40%)
QGEN : 54.34 (+0.35%)
LabCorp (LH) Bolsters RA Testing by Adding Myriad's Vectra

According to LabCorp (LH), Vectra and the related IP and other assets from Myriad Genetics' autoimmune business complement its prior business activity.

LH : 295.93 (-0.30%)
HSIC : 77.47 (-1.15%)
MYGN : 33.72 (+3.37%)
NVST : 42.53 (-2.12%)
Myriad Genetics Completes Sale of Myriad Autoimmune's Vectra Testing Business to LabCorp

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has completed the sale of select operating assets and intellectual property (IP), including...

MYGN : 33.72 (+3.37%)
LH : 295.93 (-0.30%)
Only 8% of people remain hopeful after depression medication fails them, according to GeneSight(R) Mental Health Monitor nationwide survey

Depression medication trial and error is far too common - and may result in additional mental health challenges.

MYGN : 33.72 (+3.37%)
Illumina (ILMN), Merck Ink Cancer Companion Diagnostics Deal

Illumina (ILMN) collaborated with Merck to develop and commercialize companion diagnostics to identify ovarian cancer patients with positive HRD status for treatment with LYNPARZA.

MRK : 71.68 (-0.40%)
ILMN : 447.01 (-0.65%)
MYGN : 33.72 (+3.37%)
MRNA : 430.05 (-2.41%)
Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations

/PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Merck (known as MSD outside and ) today announced a partnership to develop and commercialize tests that identify genetic mutations used in the assessment...

ILMN : 447.01 (-0.65%)
MYGN : 33.72 (+3.37%)
Agilent (A) Boosts PD-L1 IHC 22C3 pharmDX Assay Use in Europe

Agilent Technologies (A) boosts presence in the companion diagnostics market by expanding the use of PD-L1 IHC 22C3 pharmDx assay for esophageal cancer treatment in Europe.

A : 173.94 (+0.38%)
TMO : 596.80 (+6.49%)
MYGN : 33.72 (+3.37%)
APPS : 66.86 (+5.86%)
Tryp Therapeutics Appoints Dennis Langer, M.D., J.D. as Senior Advisor

San Diego, California--(Newsfile Corp. - August 18, 2021) - (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases...

GSK : 38.93 (-0.46%)
MYGN : 33.72 (+3.37%)
NTEC : 9.63 (-12.48%)
TRYP.CN : 0.400 (-1.23%)
TRYPF : 0.3134 (-1.85%)
Myriad Genetics (MYGN) Q2 Earnings Beat, Gross Margin Rises

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q2 sales despite a challenging business environment.

MYGN : 33.72 (+3.37%)
WST : 448.62 (-1.29%)
CHE : 475.52 (-0.54%)
EHC : 75.92 (-0.64%)
Theragnostics Strengthens Board of Directors with Key Appointments

/PRNewswire/ -- Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces today the appointments of Dr and Professor as Non-Executive Directors...

GSK : 38.93 (-0.46%)
NTEC : 9.63 (-12.48%)
MYGN : 33.72 (+3.37%)
BTX : 11.95 (-3.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Myriad Genetics, Inc. is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Myriad is the pioneer and leader in molecular diagnostics, offering...

See More

Key Turning Points

3rd Resistance Point 35.43
2nd Resistance Point 34.59
1st Resistance Point 34.15
Last Price 33.72
1st Support Level 32.87
2nd Support Level 32.03
3rd Support Level 31.59

See More

52-Week High 36.95
Last Price 33.72
Fibonacci 61.8% 27.33
Fibonacci 50% 24.36
Fibonacci 38.2% 21.38
52-Week Low 11.76

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar